Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetics and ovarian carcinoma

H T Lynch1, M J Casey, J Lynch

  • 1Department of Preventive Medicine, Creighton University School of Medicine, Omaha, NE, USA.

Seminars in Oncology
|June 20, 1998
PubMed
Summary

Ovarian cancer, affecting 1% of women, involves genetic mutations in genes like BRCA1/BRCA2 and DNA mismatch repair genes. Early detection is crucial for survival, as many genetic factors contribute to its development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular stemness identifies high-risk ductal carcinoma <i>in situ</i> and offers a therapeutic interception opportunity.

bioRxiv : the preprint server for biology·2026
Same author

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.

Oncogene·2016
Same author

Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.

Oncogene·2013
Same author

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Oncogene·2013
Same author

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Gynecologic oncology·2013

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Ovarian cancer affects 1% of American women, causing over 14,000 deaths annually.
  • Early detection is critical, with a 5-year survival rate below 20% for advanced stages.
  • The disease originates from the ovarian surface epithelium, likely involving a multi-step genetic mutation process.

Purpose of the Study:

  • To review the genetic underpinnings of ovarian cancer.
  • To highlight the role of tumor suppressor genes and proto-oncogenes.
  • To discuss the implications of genetic screening and counseling for high-risk individuals.

Main Methods:

  • Review of genetic alterations in ovarian tumors, including proto-oncogene activation and tumor suppressor gene inactivation.
  • Identification and analysis of key genes such as BRCA1, BRCA2, and DNA mismatch repair (MMR) genes.

Related Experiment Videos

  • Discussion of current screening protocols for individuals with hereditary cancer predispositions.

    • Main Results:

    • Proto-oncogenes (AKT2, Ki-RAS) and tumor suppressor genes (TP53) are implicated in ovarian cancer development.
    • Mutations in BRCA1 and BRCA2 are responsible for most hereditary ovarian cancers.
    • Increased ovarian cancer risk is observed in Lynch II syndrome (HNPCC) patients due to MMR gene mutations.

    Conclusions:

    • Genetic mutations, including those in BRCA1, BRCA2, and MMR genes, play a significant role in ovarian cancer.
    • Genetic screening and counseling are vital for managing high-risk women.
    • Further research is needed to discover more genes involved in gynecologic malignancies and understand the clinical significance of known cancer genes.